Vericel Corp
No SEC Form 4 filings for $VCEL in the last 30 days.
See all $VCEL insider activity →MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.
Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program Total Revenue Increased 22% to $77.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VCEL (Vericel Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VCEL coverage spans financial news, insider activity and earnings.
VCEL benefits from the partnership and may see incremental upside from the expanded program.
Guidance raise and first buyback authorization are near-term catalysts, with margin guidance unchanged but EBITDA expansion expected to accelerate in 2027.
Raised guidance plus a new $200M buyback signals improving cash generation and supports a bullish near-term re-rating, though execution risk remains in commercial franchises.
Routine insider selling by a senior officer; likely limited incremental signal versus broader fundamentals.
Routine insider sale disclosure; signals liquidity/portfolio management more than fundamental change.
AlphAI scores every news story that mentions VCEL with an AI model for sentiment and relevance, and aggregates insider trades from Vericel Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
2 min readVericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.
4 min readVericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program Total Revenue Increased 22% to $77.
6 min readFlynn Sean C. (Chief Legal Officer) sold 15,000 shares of Vericel Corp (VCEL) at $45.64 ($0.68M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
1 min readFlynn Sean C. (Chief Legal Officer) sold 15,000 shares of Vericel Corp (VCEL) at $40.21 ($0.60M total) on 2026-06-18 under a Rule 10b5-1 trading plan.
2 min readHopper Jonathan Mark (Chief Medical Officer) sold 4,375 shares of Vericel Corp (VCEL) at $35.00 ($0.15M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
3 min readVericel Corporation (VCEL) has amended its corporate bylaws to reflect its new global headquarters located at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The amendment was approved by the Board of Directors and became effective on May 18, 2026. This change ensures that the company's official corporate records align with its updated principal executive office address.
1 min readVanguard Capital Management has disclosed a 5.11% beneficial ownership stake in Vericel (NASDAQ: VCEL), amounting to 2,603,128 shares of common stock. This is reported via a Schedule 13G SEC filing, indicating Vanguard holds these shares for investment purposes across various affiliated funds and client accounts. The filing specifies Vanguard's sole voting power over 372,372 shares and sole dispositive power over all 2,603,128 shares.
2 min readCAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at ...
3 min readCAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at ...
3 min read
